Treatment for muscle wasting improved survival in pre-clinical cancer model

Researchers from the University of Jyväskylä in Finland have found that continued treatment of muscle wasting with a soluble growth factor receptor protein, produced at the University of Helsinki, improved survival in a pre-clinical cancer model without affecting the tumor size. This effect was not found when the mice were treated with the recombinant protein only prophylactically before cancer.

"These findings, together with a few earlier rodent studies as well as a rather large body of epidemiological evidence in humans, have led to suggestions of a possible causal link between the preservation of muscle mass and improved survival. It can be speculated that the preservation of some specific, vital muscles, such as the major respiratory muscles, may be especially important for this effect," says PhD student Tuuli Nissinen and the Academy of Finland Research Fellow and group leader Juha Hulmi.

"However," they continue, "our results cannot rule out some muscle-independent effects of our protein. It seems that circulating pro-inflammatory cytokines, physical activity, or hepatic and splenic physiology, which were all altered in cancer, may not be determining factors for improved survival with the soluble growth factor receptor, more specifically soluble activin receptor 2B."